Oncotide: SETting up phosphatases
Oncotide SET antagonists enhance phosphatase activity, disrupt cancer signaling
Oncotide Pharmaceuticals Inc. believes it has found a way to deactivate the phosphorylation that is a driver of oncogenic signaling, an approach that could provide an alternative or add-on to kinase inhibitors for blocking growth of tumor cells.
Rather than inhibiting kinases to restore normal phosphorylation and reduce the signaling of up-regulated oncogenic pathways, Oncotide is developing SET inhibitors to promote dephosphorylation of the oncogenic signaling molecules.
President and CSO Dale Christensen said disruptions in both kinase and